New Johns Hopkins Study Links Alexithymia to Worsening Chronic Pain Interference

Chronic pain affects millions worldwide, disrupting daily life, work, and relationships. A groundbreaking new study from Johns Hopkins University School of Medicine has uncovered a critical link between emotional processing difficulties and the progression of chronic pain. Specifically, the research demonstrates how challenges in identifying and expressing emotions—known as alexithymia—can lead to heightened psychological distress, ultimately amplifying pain's interference with everyday activities. This longitudinal investigation provides fresh insights into why some individuals experience worsening pain outcomes over time, offering hope for more targeted interventions in pain management.

Conducted over two years with 1,453 adults across the United States living with various chronic pain conditions, the study reveals that alexithymia acts as a precursor rather than a byproduct of pain escalation. By pinpointing psychological distress, including anxiety and depression, as a key mediator, the findings underscore the need to address emotional awareness in comprehensive treatment plans. As universities like Johns Hopkins continue to lead in this interdisciplinary field, blending psychology, neuroscience, and rehabilitation medicine, these discoveries could transform how chronic pain is understood and treated in academic and clinical settings.

Defining Alexithymia: A Barrier to Emotional Insight

Alexithymia, derived from Greek roots meaning 'no words for emotions,' refers to a personality trait characterized by significant challenges in recognizing, identifying, describing, and expressing one's own feelings. Individuals with high levels of alexithymia often struggle to differentiate emotional experiences from physical sensations, leading to a reliance on externally oriented thinking—focusing more on concrete details than internal states. This trait is not a mental disorder but a dimensional construct, present on a spectrum in the general population.

The standard assessment tool is the Toronto Alexithymia Scale-20 (TAS-20), a self-report questionnaire comprising 20 items divided into three subscales: Difficulty Identifying Feelings (DIF), which measures problems recognizing personal emotions; Difficulty Describing Feelings (DDF), assessing verbal expression challenges; and Externally Oriented Thinking (EOT), indicating a preference for logical over imaginative or emotional processing. Scores above 61 typically indicate clinically significant alexithymia. In everyday terms, someone with alexithymia might feel physical tension during stress but be unable to label it as 'anxiety,' potentially exacerbating unresolved emotional buildup.

Research from various universities has shown alexithymia prevalence around 10% in the general population, rising notably higher among those with chronic conditions. This emotional disconnect can hinder coping mechanisms, making it harder to seek support or engage in self-regulation strategies essential for well-being.

The Johns Hopkins Study: Unraveling Temporal Pathways

Published in Health Psychology on March 26, 2026, the study titled 'Temporal Pathways Between Alexithymia, Psychological Distress, and Pain: An Autoregressive Mediation Analysis' was led by senior author Rachel V. Aaron, Ph.D., an associate professor in the Department of Physical Medicine and Rehabilitation at Johns Hopkins University School of Medicine. Co-authors include Scott G. Ravyts, Jennifer S. De La Rosa, Claudia M. Campbell, and Chung Jung Mun, reflecting a collaborative effort across rehabilitation and pain research expertise.Read the abstract on PubMed.

This prospective cohort study tracked participants at baseline, 12 months, and 24 months, using validated instruments: TAS-20 for alexithymia, Brief Pain Inventory subscales for pain severity and interference, and Patient-Reported Outcomes Measurement Information System (PROMIS) measures for anxiety, depression, and overall psychological distress. Advanced autoregressive mediation models analyzed directional relationships, controlling for prior levels of each variable to isolate causal pathways.

The cohort represented diverse chronic pain types, including musculoskeletal, neuropathic, and fibromyalgia-related conditions, ensuring broad applicability. Funded partly by National Institutes of Health grants, the research highlights Johns Hopkins' commitment to innovative, data-driven approaches in pain science.

Key Findings: From Emotions to Distress to Daily Disruption

The study's most compelling revelation is the indirect pathway: elevated baseline alexithymia significantly predicted greater psychological distress at the one-year mark, which in turn forecasted increased pain interference at two years. Pain interference here means the degree to which pain hampers sleep, work, mood, and social functioning—not raw intensity, which showed no mediated link.

Crucially, reverse causation was absent; worsening pain did not predict later alexithymia, positioning emotional difficulties as a risk factor. Dr. Aaron noted, 'Greater difficulties identifying one's own feelings can lead to greater symptoms of psychological distress, including symptoms of depression and anxiety. This in turn can lead to greater difficulties managing chronic pain.' These temporal dynamics provide the first robust evidence of how alexithymia unfolds to impair quality of life over time.Johns Hopkins press release.

Photo by Zander Betterton on Unsplash

Prevalence and Broader Statistics on Chronic Pain

According to the Centers for Disease Control and Prevention (CDC), chronic pain—defined as persistent pain on most days for three months or longer—affects 24.3% of U.S. adults as of recent 2023 data, with 8.5% experiencing high-impact chronic pain that substantially limits life or work activities.CDC Data Brief. Globally, estimates suggest one in five adults grapple with chronic pain, imposing enormous healthcare and economic burdens.

Meta-analyses, including one by Aaron in 2019, confirm alexithymia is elevated in chronic pain populations, with up to 26% meeting clinical cutoffs compared to about 10% in the general population. Factors like gender, trauma history, and comorbidities amplify risks, with women and those with fibromyalgia showing higher rates.

• General population alexithymia: ~10%
• Chronic pain patients: 20-50% across studies
• U.S. chronic pain prevalence: 24.3% adults
• High-impact cases: 8.5%, severely limiting function

Mechanisms: How Emotional Blind Spots Fuel Pain Cycles

Alexithymia disrupts interoception—the brain's ability to sense internal bodily signals—blurring lines between emotions and physical pain. Unprocessed feelings manifest somatically, heightening central sensitization where the nervous system amplifies pain signals. Psychological distress mediates this by sustaining a feedback loop: poor emotional awareness breeds anxiety/depression, which lowers pain thresholds and coping capacity.

Step-by-step: (1) Emotional event occurs; (2) Individual fails to identify/label it (DIF/DDF); (3) Distress accumulates without outlet; (4) Hypervigilance to bodily sensations increases; (5) Pain interference escalates, affecting sleep, mobility, concentration. Neuroimaging from related university studies shows altered activity in the anterior cingulate cortex and insula, hubs for emotion-pain integration.

Treatment Innovations: Emotional Awareness and Expression Therapy (EAET)

Wayne State University researcher Mark A. Lumley, Ph.D., pioneered Emotional Awareness and Expression Therapy (EAET), a neuroscience-informed intervention showing promise for alexithymia-related chronic pain. EAET guides patients through emotional exposure, 'empty chair' dialogues, and role-plays to process suppressed feelings like anger or grief, reducing pain by 30-50% in trials.

Unlike traditional cognitive-behavioral therapy, EAET emphasizes uncovering psychosocial contributors over symptom suppression. University-led randomized controlled trials, including recent ones for fibromyalgia and low back pain, report sustained gains in emotional processing and function. Integrating TAS-20 screening could personalize EAET for high-alexithymia cases.

• Core EAET components: Education on emotion-pain links, exposure to avoided feelings, expressive writing/role-play, skill-building for daily use
• Benefits: Reduced pain intensity/interference, lower distress, improved quality of life
• Evidence: Multiple RCTs from Wayne State and collaborators

University Research Landscape: Leading Institutions

Beyond Johns Hopkins and Wayne State, institutions like King's College London validate alexithymia measures in pain cohorts, while University of Bologna explores somatization links. Canadian universities, such as University of Ottawa, investigate adolescent alexithymia-pain trajectories. This global academic push integrates psychology, neurology, and rehab, fostering multidisciplinary clinics.

In higher education, such research informs training for future clinicians and supports faculty in pain psychology. Programs at these universities offer fellowships blending clinical trials with emotional neuroscience.

Photo by explorenation # on Unsplash

Real-World Implications and Case Examples

Consider a university professor with fibromyalgia: initial back pain evolves into debilitating interference due to unaddressed grief from career setbacks. TAS-20 reveals high DIF; EAET helps label emotions, breaking the cycle. Real cases from clinic trials mirror study findings—patients report 20-40% function gains post-intervention.

For academics under stress, alexithymia risks burnout-pain comorbidity. Proactive screening in campus health services could prevent escalation.

Challenges, Solutions, and Future Outlook

Challenges include stigma around 'emotional' pain treatments and measurement limitations (self-report bias). Solutions: Hybrid telehealth EAET, AI-assisted emotion tracking apps from university spin-offs, longitudinal trials targeting DIF subscale.

Future research may explore genetic/environmental alexithymia factors and pharmacotherapy adjuncts. With rising chronic pain amid aging populations, university-led innovations promise scalable, empathetic care.